Licensing · Latin America · Announced 22 May 2026
Polpharma Biologics → Tuteur
Polpharma Biologics granted Argentina's Tuteur exclusive Latin American rights, excluding Brazil, to commercialise an unnamed biosimilar for autoimmune disease, with regulatory submission expected within three years.
Parties: Polpharma Biologics (Switzerland) → Tuteur (Argentina)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Latin America excluding Brazil
- Therapeutic area
- Immunology / Inflammation
- Asset
- Biosimilar candidate (not named)
- Announced
- 22 May 2026
Our analysis
Why this matters
Polpharma Biologics and Tuteur signed an exclusive licensing agreement, reported on 22 May 2026, to commercialise a biosimilar for an autoimmune disease across Latin America, excluding Brazil. The molecule was not named. Regulatory submission is anticipated within the next three years. Financial terms were not disclosed.
The deal fills in Polpharma's regional map: it licensed Brazil to Libbs Farmacêutica in December 2025 and signed MS Pharma for MENA (guselkumab, ocrelizumab and vedolizumab biosimilars) in September 2025.
The full analysis is free to read with a work email on this page.
Source: Pearce IP